Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Levofloxacin | Tavanic | 4.5. Interactions with other medicinal products | Interactions with antidiabetic agents. Levofloxacin may produce false-positive urine screening results for opiates | Apr,2023 |
| Secukinumab | Cosentyx | 4.8 Undesirable effects | Pyoderma gangrenosum | Feb,2023 |
| Nirmatrelvir/Ritonavir | Paxlovid | 4.5. Interactions with other medicinal products | Interactions with Sirolimus | Apr,2023 |
| Vardenafil | Levitra | 4.4 Special warnings and precautions for use, 4.5. Interactions with other medicinal products" | Interactions with strong Cytochrome (CYP3A4) inhibitors or moderate Cytochrome (CYP3A4) increases plasma concentrations of vardenafil Cobicistat with Vardenafil can result in increased plasma concentrations of Vardenafil | Apr,2023 |
| Methoxyflurane | Penthrox | 4.4 , Special Warnings and Special Precautions for Use | Respiratory depression | Feb,2023 |
| Patiromer | Veltassa | 4.5. Interactions with other medicinal products | Advise patients who are taking other oral medication that separation of dosing of Veltassa by at least 3 hours | Apr,2023 |